The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

SiftedEurope

UK Sovereign AI Fund in talks to back £500m raise for drug discovery startup

September 18

Head of ventures Josephine Kant is reportedly set to join Potential Sciences’ board.

Read at Sifted ↗

One letter a week, in your inbox.

Latest

UK Sovereign AI Fund in talks to back £500m raise for drug discovery startup

More from Sifted on Accept All

EuropeEurope's AI moment is moving from hype to execution Sifted

EuropeDeepMind researcher’s new AI lab nears $4bn valuation, reports say Sifted

EuropeAre VCs doing their AI safety due diligence? Sifted

EuropeWhy Polish startups are growing faster than ever Sifted

EuropeExein raises $270m to fight AI hackers, doubles valuation Sifted

EuropeDoes Europe have a voice in AI safety? Sifted